From four European payer perspectives, DRV/r-based antiretroviral therapy is predicted to be cost effective compared with currently available control PIs, when both are used with an OBR in treatment-experienced, HIV-1-infected adults who failed to respond to more than one PI-containing regimen.
From the perspective of Belgian, Italian, Swedish and UK payers, DRV/r 600/100 mg bid-based HAART is predicted to be cost effective compared with LPV/r 400/100 mg bid-based therapy, when used to manage treatment experienced, lopinavir-naive, PI-resistant, HIV-infected adults with a broad range of previous PI use/failure.
Darunavir-based HAART may lower non-antiretroviral-related costs compared with control PI-based therapy in highly treatment-experienced, HIV-infected patients during the first year of therapy by improving patients' CD4 cell counts. These costs could partly/fully offset the increased acquisition cost of DRV/r in this patient population over the same period.
The effects of chloramphenicol (CAP) and thiamphenicol (TAP) on the outcome of Chlamydiapsittaci infection in chick embryos were compared. CAP administered along with Chlamydia reduced embryo mortality rates but showed no appreciable effects when its injection was delayed. On the contrary, TAP caused a high rate of embryo survival in both experimental situations. Statistical analysis of the results showed that differences in the survival rates following CAP and TAP administration are significant. Metabolic pathways in chick embryos of the antibiotics assayed differed remarkably in that CAP undergoes a quicker inactivation, which could even justify the better activity showed by TAP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.